natgillin/translations-raw huggingface dataset:
Phosphate buffer solution Lyophilisate: Whitish freeze-dried lyophilisate. 
raztopina s fosfatnim pufrom Liofilizat: Belkast liofilizat posušen z zamrzovanjem.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box for solvent (10 x 10 ml and 10 x 50 ml) 
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla za vehikel (10x10 ml merkov in 10x50 ml)
5 doses 
5 odmerkov
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box for lyophilisate (10 x 5 doses and 10 x 25 doses) 
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla za liofilizat (10x5 odmerkov in 10x25 odmerkov)
Cardboard box with 1 lyophilisate vial of 25 doses and 1 vial of 50 ml of solvent. 
Kartonska škatla z 1 vialo liofilizata s 25 odmerki in 1 vialo s 50 ml vehikla.
Cardboard box with 10 lyophilisate vials of 25 doses. 
Kartonska škatla z 10 vialami liofilizata s 25 odmerki.
Cardboard box with 1 lyophilisate vial of 5 doses and 1 vial of 10 ml of solvent. 
Kartonska škatla z 1 vialo liofilizata s 5 odmerki in 1 vialo z 10 ml vehikla.
Peel the top off the aluminium cap on the vial containing the solvent, and withdraw 10 ml. 
Odlepite vrh z aluminijaste zaporke na viali z vehiklom in v injekcijsko brizgo povlecite 10 ml. 2.
Shelf life of the veterinary medicinal product as packaged for sale: 15 months. 
Rok uporabnosti zdravila v pakiranju za prodajo: 15 mesecev Rok uporabnosti po rekonstituciji v skladu z navodili: uporabite takoj.
Cardboard box with 10 lyophilisate vials of 5 doses. 
Kartonska škatla z 10 vialami liofilizata s 5 odmerki.
Each dose of 2 ml contains: Live attenuated bovine respiratory syncytial virus, strain Lym-56 ................... 104.7 - 6.5 CCID50 
En 2 ml odmerek vsebuje: živ oslabljen bovini respiratorni sincicijski virus, sev Lym-56 ........................ 104,7-6,5 CCID50
21 days after administration of one dose by the nasal route. 
Nastop imunosti: 21 dni po dajanju enega odmerka prek nosu.
Cardboard box with 10 vials of 10 ml of solvent. 
Kartonska škatla z 10 vialami z 10 ml vehikla.
Each dose of 2 ml contains: Live attenuated bovine respiratory syncytial virus, strain Lym-56 ................... 104.7 - 6.5 CCID50* 
En 2 ml odmerek vsebuje: živ oslabljen bovini respiratorni sincicijski virus, sev Lym-56 ........................ 104,7-6,5 CCID50*
Phosphate buffer solution 
Vehikel: raztopina s fosfatnim pufrom
Lyophilisate for suspension for injection or nasal spray 
liofilizat za suspenzijo za injiciranje ali pršilo za nos
Cardboard box with 10 vials of 50 ml of solvent. 
Kartonska škatla z 10 vialami s 50 ml vehikla.
Lyophilisate: Whitish freeze-dried lyophilisate. 
Liofilizat: dekstran saharoza želatina
NASYM lyophilisate and solvent for suspension for injection or nasal spray for cattle. 
NAVODILO ZA UPORABO NASYM liofilizat in vehikel za suspenzijo za injiciranje ali pršilo za nos za govedo
NASYM lyophilisate for suspension for injection or nasal spray for cattle 
NASYM liofilizat za suspenzijo za injiciranje ali pršilo za nos za govedo
Live attenuated bovine respiratory syncytial virus (BRSV), strain Lym-56 ..... 104.7 - 6.5 CCID50* *Cell culture infectious dose 50% 
živ oslabljen bovini respiratorni sincicijski virus (BRSV), sev Lym-56 .......... 104,7-6,5 CCID50*
Lyophilisate and solvent for suspension for injection or nasal spray 
liofilizat in vehikel za suspenzijo za injiciranje ali pršilo za nos
Live attenuated bovine respiratory syncytial virus, strain Lym-56 ................... 104.7 - 6.5 CCID50* *Cell culture infectious dose 50% 
živ oslabljen bovini respiratorni sincicijski virus, sev Lym-56 ........................ 104,7-6,5 CCID50*
Live attenuated bovine respiratory syncytial virus, strain Lym-56. 
NASYM liofilizat in vehikel za suspenzijo za injiciranje ali pršilo za nos za govedo živ oslabljen bovini respiratorni sincicijski virus, sev Lym-56.
Solvent vials (10 ml and 50 ml) NAME OF THE VETERINARY MEDICINAL PRODUCT 
OVOJNINAH Viale z vehiklom (10 ml in 50 ml)
Marketing authorisation holder and manufacturer responsible for batch release: Laboratorios Hipra, S.A. 
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za sproščanje serij:
Vial of lyophilisate (5 doses and 25 doses) NAME OF THE VETERINARY MEDICINAL PRODUCT 
OVOJNINAH Viala z liofilizatom (5 odmerkov in 25 odmerkov)
Avda. 
Rp-Vet.
Packaging Content Package size Withdrawal Period 
Poti dajanja Pakiranje Vsebina Velikost pakiranja
Pharmaceut ical Form 
Farmacevtska oblika
Invented Name 
Številka EU Izmišljeno ime Jakost
Intravenous use vial (glass) 
Intravensko Viala (steklo)
Powder for concentrate for solution for infusion 
140 mg Prašek za koncentrat za raztopino za infundiranje
EMA/808930/2011 corr. EMEA/H/C/001225 
EMA/990694/2011 EMEA/H/C/001225
Treatment may continue for as long as the doctor considers that the patient is benefiting from it. 
Zdravljenje lahko traja toliko časa, dokler zdravnik meni, da bolniku koristi.
The very first dose at the start of the treatment should be taken under medical supervision. 
Prvi odmerek na začetku zdravljenja je treba uporabiti pod zdravniškim nadzorom.
The recommended dose is one capsule twice daily, taken as close as possible to 12 hours apart. 
Priporočeni odmerek je ena kapsula dvakrat na dan in jo je treba uporabiti v čim bolj točnem razmiku 12 ur.
The European Commission granted a marketing authorisation valid throughout the European Union for Colobreathe on 13 February 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Colobreathe, veljavno po vsej Evropski uniji, odobrila dne 13. februarja 2012.
They are not to be inhaled using any other device. 
Vdihniti se ne smejo z nobenim drugim pripomočkom.
FEV1 is the most air a person can breathe out in one second. 
FEV1 je največja prostornina zraka, ki jo lahko bolnik izpihne v eni sekundi.
The full EPAR for Colobreathe can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Colobreathe je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The packs will contain information on the need to comply with treatment, instructions on how to use the medicine and information on side effects. 
Ti bodo vsebovali informacije o potrebi po upoštevanju zdravljenja, navodila o uporabi zdravila in informacije o neželenih učinkih.
For more information about treatment with Colobreathe, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Colobreathe preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
In addition, the Committee noted that patients generally prefer inhaling powder to using a nebuliser. 
Poleg tega je odbor navedel, da imajo bolniki navadno raje inhalacijski prašek kot nebulator.
This is a summary of the European public assessment report (EPAR) for Colobreathe. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Colobreathe.
What measures are being taken to ensure the safe use of Colobreathe? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Colobreathe?
The effects of Colobreathe were first tested in experimental models before being studied in humans. 
Učinki zdravila Colobreathe so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The main measure of effectiveness was based on the improvement in FEV1, adjusted for the patients' age and height, after 24 weeks. 
Glavno merilo za učinkovitost je temeljilo na izboljšanju vrednosti FEV1, prilagojene glede na bolnikovo starost in telesno maso, po 24 tednih.
The Committee therefore decided that the benefits of Colobreathe are greater than its risks and recommended that it be given marketing authorisation. 
Na podlagi navedenega je Odbor zaključil, da so koristi zdravila Colobreathe večje od z njim povezanih tveganj, in priporočil, naj se zanj odobri dovoljenje za promet.
The company that makes Colobreathe will supply education packs to patients and healthcare professionals. 
Družba, ki izdeluje zdravilo Colobreathe, bo bolnikom in zdravstvenim delavcem priskrbela izobraževalne komplete.
It is available as capsules containing a powder for inhalation using an inhaler device. 
Na voljo je v obliki kapsul, ki vsebujejo prašek za inhalacijo z uporabo inhalacijskega pripomočka.
If the patient is also receiving other treatments for cystic fibrosis, they should be taken in the following order: inhaled bronchodilator, chest physiotherapy, other inhaled medicines and then Colobreathe. 
Če bolnik za zdravljenje cistične fibroze prejema tudi druge oblike zdravljenja, jih je treba uporabljati v naslednjem vrstnem redu: inhalacijski bronhodilatator, fizioterapija prsnega koša, druga inhalacijska zdravila, zdravilo Colobreathe.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Colobreathe. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Colobreathe, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Colobreathe 
Druge informacije o zdravilu Colobreathe
Inhalation may also lead to coughing or bronchospasm (tightening of the muscles in the airway), which may be controlled by first treating the patients with inhaled beta-2 agonist medicines. 
Vdihavanje lahko povzroči tudi kašelj ali bronhospazem (krčenje mišic v dihalnih poteh), kar se lahko nadzira tako, da se bolniki najprej zdravijo z inhalacijskimi zdravili, v katerih je agonist adrenergičnih receptorjev beta-2.
Among patients that completed the study, the improvement in FEV1 adjusted for age and height was 0.39% with Colobreathe compared with 0.78% with tobramycin. 
Pri bolnikih, ki so končali študijo, je bilo izboljšanje vrednosti FEV1, prilagojene glede na starost in telesno višino, 0,39-odstotno pri zdravilu Colobreathe in 0,78-odstotno pri tobramicinu.
EPAR summary for the public colistimethate sodium 
Povzetek EPAR za javnost natrijev kolistimetat
The most common side effects seen with Colobreathe in studies were: unpleasant taste, cough, throat irritation, difficulty breathing and dysphonia (difficulty speaking). 
Najpogostejši neželeni učinki, ki so jih v študijah opazili pri zdravilu Colobreathe, so bili neprijeten okus, kašelj, draženje grla, težave z dihanjem in disfonija (težave z govorom).
Colobreathe must not be used in people who are hypersensitive (allergic) to colistimethate sodium or to colistin sulphate or polymyxin B. 
Zdravila Colobreathe ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) natrijev kolistimetat, kolistinijev sulfat ali polimiksin B.
What benefit has Colobreathe shown during the studies? 
Kakšne koristi je zdravilo Colobreathe izkazalo med študijami?
Colistimethate sodium is a well-known antibiotic that has been used for several years to treat lung infection in cystic fibrosis patients and is available in the form of a solution used with a nebuliser (a machine that changes a solution into an aerosol that the patient can breathe in). 
Natrijev kolistimetat je dobro znan antibiotik, ki se že mnoga leta uporablja za zdravljenje pljučne okužbe pri bolnikih s cistično fibrozo, in je na razpolago v obliki raztopine, ki se uporablja z nebulatorjem (pripomočkom, ki raztopino spremeni v aerosol, kar bolniku omogoči inhalacijo).
The contents of Colobreathe capsules are inhaled using a powder inhaler called Turbospin. 
Vsebina kapsul Colobreathe se vdihne z inhalatorjem, imenovanim Turbospin.
The side effects seen with Colobreathe were considered acceptable. 
Neželeni učinki, opaženi pri zdravilu Colobreathe, so bili ocenjeni kot sprejemljivi.
Polymyxins target a group of bacteria called Gram-negative bacteria, which includes P. aeruginosa, because their cell membranes contain a high level of phospholipids. 
Polimiksini napadejo skupino bakterij, imenovanih gramnegativne bakterije, ki vključujejo P. aeruginosa, saj njihove celične membrane vsebujejo visoko raven fosfolipidov.
Cystic fibrosis is an inherited disease that affects the cells in the lungs and the glands in the gut and pancreas which secrete fluids such as mucus and digestive juices. 
Cistična fibroza je dedna bolezen, ki prizadene celice v pljučih ter žlezah v črevesu in trebušni slinavki, ki izločajo tekočine, kot so sluz in prebavni sokovi.
The accumulation of mucus in the lungs allows bacteria to grow more easily causing infections, lung damage and breathing problems. 
Kopičenje sluzi v pljučih bakterijam olajša rast, kar povzroča okužbe, poškodbo pljuč in težave z dihanjem.
The patients' condition had been stabilised by treatment with tobramycin before the study. 
Pred študijo se je stanje bolnikov stabiliziralo z zdravljenjem s tobramicinom.
In cystic fibrosis these fluids become thick and viscous, blocking the airways and the flow of digestive juices. 
Pri cistični fibrozi te tekočine postanejo goste in viskozne, kar ovira dihalne poti in pretok prebavnih sokov.
Colobreathe is a medicine that contains the active substance colistimethate sodium. 
Colobreathe je zdravilo, ki vsebuje zdravilno učinkovino natrijev kolistimetat.
For the full list of all side effects reported with Colobreathe, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Colobreathe, glejte navodilo za uporabo.
The active substance in Colobreathe, colistimethate sodium, is an antibiotic from the polymyxin group. 
Zdravilna učinkovina v zdravilu Colobreathe, natrijev kolistimetat, je antibiotik iz skupine polimiksinov.
No more serious side effects were seen with Colobreathe than with tobramycin. 
Pri zdravilu Colobreathe niso opazili več resnih neželenih učinkov kot pri tobramicinu.
Colobreathe compared well with the tobramycin treatment, considering the fact that the patients were already stabilised on tobramycin nebuliser. 
Zdravilo Colobreathe je bilo dobro v primerjavi z zdravljenjem s tobramicinom ob upoštevanju, da so bili bolniki že stabilizirani z nebulatorjem s tobramicinom.
The CHMP concluded that the modest improvement in FEV1 seen with Colobreathe was sufficient evidence of the medicine's effectiveness, given that larger improvements would not be expected in patients whose condition was already stabilised on tobramycin nebuliser. 
Odbor CHMP je zaključil, da je bilo zmerno izboljšanje FEV1, ki so ga opazili pri zdravilu Colobreathe, zadosten dokaz učinkovitosti zdravila, pri čemer je treba upoštevati, da večjih izboljšanj pri bolnikih, pri katerih je bilo stanje že stabilizirano z nebulatorjem s tobramicinom, ni pričakovati.
What is the risk associated with Colobreathe? 
Kakšna tveganja so povezana z zdravilom Colobreathe?
Colobreathe is used to manage long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and over who have cystic fibrosis. 
Zdravilo Colobreathe se uporablja za obravnavo dolgotrajne pljučne okužbe, ki jo povzroča bakterija Pseudomonas aeruginosa pri bolnikih s cistično fibrozo, starih šest let in več.
Colobreathe was compared with another medicine, tobramycin nebuliser solution, in 380 cystic fibrosis patients aged six years and above with P. aeruginosa lung infection. 
Zdravilo Colobreathe so primerjali z drugim zdravilom, inhalacijsko raztopino tobramicina za nebulator, pri 380 bolnikih s cistično fibrozo, starih šest let ali več, ki so imeli okužbo s P. aeruginosa.
The improvements in FEV1 seen with Colobreathe were considered sufficient proof of effectiveness, considering the fact that the patients in the study were already stabilised on tobramycin nebuliser. 
Menili so, da je bilo izboljšanje vrednosti FEV1 pri zdravilu Colobreathe zadosten dokaz za učinkovitost glede na to, da so bili bolniki v študiji že stabilizirani z nebulatorjem s tobramicinom.
Colobreathe, as a powder for inhalation, is expected to be more convenient for patients than nebulisers. 
Po pričakovanjih bo zdravilo Colobreathe v obliki praška za inhalacijo priročnejše kot nebulatorji.
Bacterial lung infection with P. aeruginosa is frequent in cystic fibrosis patients. 
Pri bolnikih s cistično fibrozo je bakterijska pljučna okužba s P. aeruginosa pogosta.
Polymyxins work by disrupting the cell membrane of bacteria by interacting with certain components of the membrane called phospholipids. 
Polimiksini skupaj z nekaterimi sestavinami membrane, imenovanimi fosfolipidi, delujejo tako, da motijo delovanje celične membrane bakterij.
How has Colobreathe been studied? 
Kako je bilo zdravilo Colobreathe raziskano?
Why has Colobreathe been approved? 
Za kaj je bilo zdravilo Colobreathe odobreno?
What is Colobreathe? 
Kaj je zdravilo Colobreathe?
What is Colobreathe used for? 
Za kaj se zdravilo Colobreathe uporablja?
How does Colobreathe work? 
Kako zdravilo Colobreathe deluje?
How is Colobreathe used? 
Kako se zdravilo Colobreathe uporablja?
In these studies only limited efficacy was shown. 
Študiji sta pokazali zgolj omejeno učinkovitost.
After excluding one double entry, 1616 cases were considered for the analysis. 
Po izključitvi enega dvojnega vnosa so za analizo uporabili 1616 primerov.
Some Members States have both indications. 
V nekaterih državah članicah sta odobreni obe indikaciji.
Overall, an estimated 70%-80% of the allergy tests performed were positive. 
Skupno je bilo pozitivnih približno 70-80 % alergijskih testov.
Tetrazepam containing medicinal products are authorised in Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Latvia, Lithuania, Luxembourg, Poland, Romania, Slovakia and Spain (see Annex I for the list of tetrazepam containing medicinal products authorised in the EU). 
Zdravila, ki vsebujejo tetrazepam, so odobrena v Avstriji, Belgiji, Bolgariji, Češki republiki, Franciji, Nemčiji, Latviji, Litvi, Luksemburgu, na Poljskem, v Romuniji, na Slovaškem in v Španiji (za seznam zdravil, ki vsebujejo tetrazepam in so bila odobrena za uporabo v EU, glejte Prilogo I).
Allergic tests were performed in several cases. 
V številnih primerih so opravili alergijske teste.
In 10 cases, the diagnosis was confirmed by skin biopsy. 
V 10 primerih so diagnozo potrdili z biopsijo kože.
Severe cutaneous adverse reactions with tetrazepam are also described in published literature1,2,3,4,5,6,7,8,9,10,11. 
Resne neželene kožne reakcije na tetrazepam so opisane tudi v objavljeni literaturi 1,2,3,4,5,6,7,8,9,10,11.
The PRAC also noted that current guidelines do not refer to the use of tetrazepam in the spasticity indication. 
PRAC je upošteval tudi, da trenutne smernice ne obravnavajo uporabe tetrazepama pri indikaciji spastičnosti.
The efficacy of tetrazepam was also compared to other active drugs in controlled double blind studies: these studies did not show statistically significant difference between the groups in both indications. 
Učinkovitost tetrazepama so v nadzorovanih dvojno slepih študijah primerjali tudi z učinkovitostjo drugih aktivnih zdravil: v študijah niso opazili statistično pomembnih razlik med skupinama pri obeh indikacijah.
These cases concerned 31 cases of SJS and 35 cases of TEN, including one case with both reactions. 
Med njimi je bilo 31 primerov SJS in 35 primerov TEN, pri čemer sta se v enem primeru pojavili obe reakciji.
Thirty-eight (38) cases were non medically-confirmed cases and 475 cases were medically-confirmed; among them, 180 cases were directly reported to the Company, 245 cases were reported by Health Authorities, and 50 cases were identified in the scientific worldwide literature. 
Osemintrideset (38) primerov ni bilo zdravniško potrjenih, medtem ko jih je 475 bilo; od tega so o 180 primerih poročali neposredno družbi, o 245 primerih so poročali pristojni zdravstveni organi, 50 primerov pa so odkrili v mednarodni znanstveni literaturi.
This is confirmed by the results of the allergic tests for which in a number of cases only tetrazepam had positive results. 
To so potrdili rezultati alergijskih testov, ki so bili v številnih primerih pozitivni samo za tetrazepam.
In addition the PRAC considered that the clinical data supporting the 6-day duration treatment benefit were insufficiently robust. 
Poleg tega je PRAC menil, da klinični podatki, s katerimi naj bi utemeljili koristnost 6-dnevnega zdravljenja, niso bili dovolj robustni.
At the date of 30 June 2012, 2382 cases with tetrazepam were registered in the French national database. 
Dne 30. junija 2012 je bilo v francoski nacionalni zbirki podatkov 2382 primerov, povezanih s tetrazepamom.
PRAC acknowledged that majority of cases reported involved the use of multiple medicinal products. 
PRAC je upošteval, da je večina primerov, o katerih so poročali, vključevala sočasno uporabo več zdravil.
In most of the cases, the causal relationship of tetrazepam was reported as possible (86% of the cases) and in some cases as probable (11% of the cases). 
V večini primerov je bil tetrazepam opredeljen kot možen vzrok (v 86 % primerih), v nekaterih primerih pa kot verjeten vzrok (v 11 % primerov).
Almost all cases with information about duration of treatment with tetrazepam, a duration of up to one month treatment was observed in most cases; in 9 cases, the duration was very short (less than 4 days). 
V skoraj vseh primerih, za katere so na voljo podatki o trajanju zdravljenja s tetrazepamom, je zdravljenje trajalo do enega meseca; v 9 primerih je bil čas zdravljenja zelo kratek (manj kot 4 dni).
The conditions for lifting the suspension of the marketing authorisations are set out in Annex III. 
Pogoji za preklic začasnega umika dovoljenj za promet so opredeljeni v Prilogi III.
Scientific conclusions and grounds for suspension of the marketing authorisations (see Annex I) 
Znanstveni zaključki in podlaga za začasen umik dovoljenj za promet z zdravili (glejte Prilogo I)
Taking into account the indications of tetrazepam, the effectiveness of a reduction of duration of treatment was questioned by the PRAC in view of the potential for repeated use. 
Glede na indikacije tetrazepama je PRAC podvomil o učinkovitosti skrajšanja trajanja zdravljenja zaradi verjetnosti večkratne uporabe.
In view of the safety concerns in relation to serious, potentially fatal, skin reactions and the limited efficacy of tetrazepam, the PRAC concluded that pursuant to Article 116 of Directive 2001/83/EC the benefit-risk balance of tetrazepam containing medicines is considered no longer favourable. 
V zvezi z varnostnimi zadržki, povezanimi z resnimi in potencialno smrtnimi kožnimi reakcijami ter majhno učinkovitostjo tetrazepama, je PRAC zaključil, da v skladu s členom 116 Direktive 2001/83/ES razmerje med tveganji in koristmi za zdravila, ki vsebujejo tetrazepam, ni več pozitivno.
Further risk minimisation measures such as additional amendments to the product information (contraindications, warnings), communication material (patient alert card, dear Health Care Professional Letter) and reduction of pack size were also considered during the discussions. 
Prav tako so med razpravo preučili dodatne ukrepe za zmanjšanje tveganja, kot so dodatne spremembe informacij o zdravilu (kontraindikacije, opozorila), gradivo za obveščanje (opozorilna kartica za bolnika, dopis za zdravstvene delavce) in zmanjšanje velikosti pakiranja.
Time to onset ranged from 1 to 3 weeks in 14 patients, while 9 cases were reported with a shorter time to onset (< 7 days) including 6 cases with a very short time to onset between 1- 3 days. 
Čas do pojava reakcij je bil pri 14 bolnikih od 1 do 3 tedne, medtem ko so v 9 primerih poročali o krajšem času (< 7 dni), pri čemer so se v 6 primerih reakcije pojavile že po 1-3 dneh.
• The PRAC considered the procedure under Article 107i of Directive 2001/83/EC, for tetrazepam containing products. 
• PRAC je obravnaval postopek v skladu s členom 107i Direktive 2001/83/ES za zdravila, ki vsebujejo tetrazepam;
Tetrazepam was the only suspected drug or had a causality score higher than the concomitant treatments in 18 out 81 cases of SJS, TEN or DRESS. 
Tetrazepam je bil edini domnevni vzrok ali pa je imel višjo oceno vzročnosti kot sočasno uporabljana zdravila v 18 od 81 primerov SJS, TEN ali DRESS.